Evidence map›Paper›PMID 38918649›Full record

SynthesisAsian Pacific journal of cancer prevention : APJCP2024

A Systematic Review of the Prevalence of Germline BRCA mutations in North Asia Breast Cancer Patients.

Polina Gervas, Molokov Yu Aleksey, Babyshkina N Nataliya, Olesya Kollantay, Choynzonov L Evgeny, Nadezda V Cherdyntseva

Abstract readSystematic Review
In one paragraph

Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Polina GervasDepartment of Cancer Research, Cancer Research Institute Tomsk, National Research Medical Center, Russian Academy of Science, Tomsk, Russia.ORCID 0000-0003-0051-8814
Molokov Yu AlekseyDepartment of Cancer Research, Cancer Research Institute Tomsk, National Research Medical Center, Russian Academy of Science, Tomsk, Russia.ORCID 0000-0002-1475-1185
Babyshkina N NataliyaDepartment of Cancer Research, Cancer Research Institute Tomsk, National Research Medical Center, Russian Academy of Science, Tomsk, Russia.ORCID 0000-0002-0562-3878
Olesya KollantayDepartment of Cancer Research, Cancer Research Institute Tomsk, National Research Medical Center, Russian Academy of Science, Tomsk, Russia.
Choynzonov L EvgenyDepartment of Cancer Research, Cancer Research Institute Tomsk, National Research Medical Center, Russian Academy of Science, Tomsk, Russia.
Nadezda V CherdyntsevaDepartment of Cancer Research, Cancer Research Institute Tomsk, National Research Medical Center, Russian Academy of Science, Tomsk, Russia.ORCID 0000-0003-1526-9013

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe BRCA1/2 mutation status testing is the global standard of care for breast cancer patients with a family history of cancer. BRCA1/2 mutations are known to be ethno-specific. For some ethnic groups of the Northern Asia (Buryats, Yakuts, Altaians, Tuvans, Khakasses, etc.) the founder mutations in the BRCA1/2 genes have not been revealed. This systematic review was conducted to assess the prevalence of BRCA1/2 mutation in breast cancer patients inhabiting Eastern Europe and Northern Asia (or Siberia).

methodsA total of 23,561 studies published between 2014 and 2024 were analyzed, of which 55 were included in the review. The literature search was conducted using RusMed, Cyberleninka, Google Scholar, eLibrary, NCBI databases (n=5) and conference papers.

resultsThe founder mutations (c.5266dupC and/or c.181T>G) of BRCA1 gene that were frequently observed in the Slav peoples were also identified in Chechens, Armenians, Bashkirs, Ukrainians, Mordovians, Mari, Kabardians, Tatars, Uzbeks, Kyrgyz, Ossetians, Khanty indigenous peoples and Adygs. For Chechens, Kabardians, Ingush, Buryats, Khakasses, Sakha, Tuvans and Armenians, rare pathogenic variants of the BRCA1/2, ATM, СНЕК2, BRIP1, NBN, PTEN, TP53, PMS1, XPA, LGR4, BRWD1 and PALB2 genes were found. No data are available about the frequency of pathogenic BRCA1/2 mutations for ethnic groups, such as the Udmurts, Komi, Tajiks, Tabasarans, and Nogais indigenous people.

conclusionThis is the first systematic review that provides the spectrum of BRCA mutations in ethnic groups of breast cancer patients inhabiting Eastern Europe and Northern Asia. It has been shown that the mutations are ethnospecific (varied widely within groups) and not all groups are equally well studied. Further studies on the ethnic specificity of BRCA gene mutations are required.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsGerm-Line MutationAsiaFemaleGenetic Predisposition to DiseaseHumansPrevalencePrognosisBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCAbreast cancerEthnic Groupsgermline variantIndigenous Peoples

Identifiers

PMID38918649
PMCPMC11382858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.